Benzinga · Aug 14, 2026
B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.
CR
NASDAQ · CRBU
Caribou Biosciences, Inc.
Healthcare · Biotechnology
$1.44
Down-$0.07 (-4.86%)
Updated Sep 10, 2026, 7:44 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 173.35M
- P/E ratio
- -1.11
- Dividend yield
- 0.00%
- 52-week range
- $1.43 – $2.49
- Volume
- 1.77M
- Avg. volume
- 2.34M
Price performance
CRBU price history
1M range · 20 trading sessions · Daily adjusted prices
CRBU closed at $1.44 after 20 trading sessions, down 15.29% for the selected period.
- Last close
- $1.44
- Period change
- -15.29%
- Period low
- $1.44
- Period high
- $1.76
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.54 | $1.54 | $1.44 | $1.44 | 1.77M |
| Sep 8, 2026 | $1.57 | $1.58 | $1.54 | $1.54 | 717.63K |
| Sep 4, 2026 | $1.57 | $1.60 | $1.55 | $1.57 | 1.33M |
| Sep 3, 2026 | $1.61 | $1.61 | $1.5325 | $1.57 | 1.35M |
| Sep 2, 2026 | $1.55 | $1.625 | $1.55 | $1.60 | 770.67K |
| Sep 1, 2026 | $1.53 | $1.59 | $1.5194 | $1.55 | 756.28K |
| Aug 31, 2026 | $1.61 | $1.63 | $1.525 | $1.54 | 1.01M |
| Aug 28, 2026 | $1.66 | $1.67 | $1.60 | $1.62 | 666.59K |
| Aug 27, 2026 | $1.67 | $1.69 | $1.64 | $1.66 | 901.15K |
| Aug 26, 2026 | $1.75 | $1.75 | $1.64 | $1.65 | 841.31K |
| Aug 25, 2026 | $1.65 | $1.76 | $1.65 | $1.76 | 1.38M |
| Aug 24, 2026 | $1.68 | $1.69 | $1.61 | $1.64 | 762.66K |
| Aug 21, 2026 | $1.64 | $1.69 | $1.615 | $1.66 | 1.16M |
| Aug 20, 2026 | $1.64 | $1.65 | $1.58 | $1.61 | 892.58K |
| Aug 19, 2026 | $1.60 | $1.66 | $1.58 | $1.64 | 1.57M |
| Aug 18, 2026 | $1.56 | $1.58 | $1.525 | $1.56 | 557.68K |
| Aug 17, 2026 | $1.57 | $1.59 | $1.55 | $1.57 | 952.14K |
| Aug 14, 2026 | $1.61 | $1.61 | $1.52 | $1.58 | 1.19M |
| Aug 13, 2026 | $1.72 | $1.72 | $1.60 | $1.61 | 1.14M |
| Aug 12, 2026 | $1.69 | $1.71 | $1.66 | $1.70 | 717.44K |
Latest CRBU news
The latest Smart Investors Daily articles mentioning CRBU.
Stock researchCompany · Overview
CRBU research
Overview
Company profile and research snapshot.
Company profile
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | B of A Securities | Buy | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 7, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 9, 2026 | Evercore ISI Group | Outperform | — |
| Feb 2, 2026 | Clear Street | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of $(0.35) per share from
Yahoo · Jun 29, 2026
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be
SeekingAlpha · Jun 26, 2026
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Cabaletta Bio (CABA) CAR-T for autoimmune disease: EULAR 2026 data, $2.90 entry, $150M raise, 2H27 BLA path, and upside potentialâread now.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
